Find partners
Next Sequence

Next Sequence

Hosted by Loretta TIOIELA

BusinessInvestingInterviews guests

Episodes

41

Latest episode

Jul 2024

Language

EN

About the show

#TechBio is changing the world and the world needs to know more about it and the most disruptive companies who want to enable humanity to face up to its next challenges as a species, from fighting genetically transmitted diseases and pandemics to preventing ageing and climate change. In this podcast, we are featuring founders, investors, university professor or tech advisers sharing with us their unique view on the challenges and opportunities behind the Bioeconomy. This podcast is produced by Next Sequence, a venture capital fund focused on supporting globally the #TechBio ecosystem, from founders to investors.

Listen to episodes

41 recent
July 26, 202449 min

TechBio Founders #32: Cleaning the world out of polyethylene plastics by turning nature's enzymes into powerful plastic degradation engines with Eleonore Eisath, Founder at Beworm

Beworm is a biotechnological start-up facing the challenge of plastic pollution. Our goal is to develop a biotic recycling process that decomposes polyethylene, a commonly used material, into its building blocks. With the help of selected microorganisms and enzymes, the long hydrocarbon chain of polymers can be split up into shorter fragments, which can be reused as raw materials. This will transform a linear process into a circular process.

June 21, 202447 min

TechBio Founders #31: Decoupling energy from fuels and emissions by building a super-star on earth with Francesco Volpe and Martin Kupp, CEO and CSO at Renaissance Fusion

Renaissance Fusion is a fusion energy company on a mission to decouple energy from fuels and emissions by building stellarators, the most efficient, steady, and stable fusion reactors on earth.

April 10, 202449 min

TechBio Investors#5-Xavier Mesnier & Perman Jorayev, VC at Verve Ventures

Verve Ventures is a network and technology-driven venture capital firm headquartered in Switzerland. Founded in 2010, Verve Ventures has grown to more than 45 team members and has become one of the most active venture investors in Europe with over 140 technology and science-driven startups in its portfolio.

March 20, 202456 min

TechBio Founders #30: Developing drug pipelines for life extension and age-related disorders with Ivan De Weber, CEO at Cortex Discovery

Cortex Discovery’s in silico drug discovery platform is based on its leading-edge AI technology which can predict molecule properties in all therapeutic fields. The accuracy of its predictions has been validated in the lab, and rivals that of experiments.

March 13, 202444 min

TechBio Investors#4- Sonal Pai, VC at First Spark Ventures

First Spark Ventures is a Deep Tech venture capital fund investing in breakthrough technologies that make the world healthier, safer, and more productive. First Spark Ventures invests in startups that have fundamental technological insights.We look for stellar teams,large accessible markets, and massive sustainable differentiation.

December 27, 202355 min

TechBio Ecosystem & Industry Partners #1-Max Dunhill, ISV Director at Oracle Cloud

Oracle partners with leading independent software vendors (ISVs) that provide complementary application and technology solutions. Oracle program for ISVs offers a wealth of best practices, lessons learned, and results to share that have transformed—and continue to transform— cloud business. It encompasses Oracle experience migrating more than 60 SaaS-based applications to Oracle Cloud Infrastructure (OCI). These applications support core enterprise functions across eight industry verticals and more than 199,000 customers across the globe.

December 13, 202343 min

TechBio Founders #29: Giving you back better insights on your research data through bioinformatic data mining using natural language without hallucinations and knowledge graph with Christopher LI, CEO at BioBox Analytics

BioBox is a software company developing a hybrid Knowledge Graph and LLM system to create a new way for scientists to converse with data, without hallucinations. Fast moving teams in biotech are deploying the BioBox platform to hit R&D milestones in target identification and validation up to 5x faster.

December 6, 202349 min

TechBio Investors#3- James Bennett , VC at Earlybird Venture Capital

Earlybird Venture Capital focuses on European technology companies. Founded in 1997, Earlybird identifies and backs exceptional early-stage companies on a pan-European basis and supports them through their growth and development phases – providing financial resources, strategic support, and access to an international network & capital markets. With EUR 2 billion under management across all fund streams, 9 IPOs, and 31 trade sales, Earlybird is one of Europe’s most established and active venture capital firms.

November 29, 202342 min

TechBio Founders #28: Improving and saving lives by producing high quality human tissue organoids in earth low orbit and space with Raphael Roettgen , CEO at Prometheus Life Technologies

Prometheus Life Technologies is a space biology company out of the University of Zurich, specialized in producing organoids in microgravity. Our team is among the world’s most foremost experts in gravitational biology, and has already successfully flown two missions to the International Space Station to grow human tissue organoids, but we are just getting started on our journey to provide health from space for Earth, and to take biotech to new heights.

November 22, 202358 min

TechBio Founders #27: Re-imagining therapeutics within the timeframe of weeks and not years through AI-based design and a high-throughput drug discovery of mini proteins with Chris BAHL, CSO at AI Proteins

AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies.

Is this your show?

Claim this listing to keep it up to date, reach guests who want to pitch you, and manage bookings with Guestify.

Claim this listing

More Business podcasts